Scynexis Prepares For NDA Filing With Second Phase III Success In VVC

 
• By Joseph Haas
  
Detailed view of a sprinter getting ready to start. Selective focus.
With two successful Phase III studies, Scynexis is ready to file novel antifungal for approval
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D